Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01348698 · ClinicalTrials.gov registry record
Evaluation of Molecular Markers in Adrenal Tumors
A clinical trial, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- 74
- Enrollment target
NCT01348698: Clinical Trial study, sponsored by National Cancer Institute (NCI).
NCT01348698 is a clinical trial that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 74 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01348698 was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- 74 participants
- Enrollment target
Study Summary
Background: \- Tumors of the adrenal gland are common. Most of them are not cancerous. However, there are no tests that can accurately tell which adrenal tumors are cancerous and which are not. The only way to tell is to remove the tumor with surgery and then examine it. Researchers have been using new methods to study samples of adrenal tissue. These methods may help identify whether the cells are or may become cancerous without an operation. This information will help doctors determine which tumors will need to be removed. Objectives: \- To collect adrenal tumor tissue biopsy samples in order to study and evaluate new methods that may help identify cancerous or precancerous cells. Eligibility: \- Individuals at least 18 years of age who have an adrenal tumor that may or may not be cancerous. Design: * Participants will be screened with a physical examination, medical history, blood and urine tests, and imaging studies. * Participants will be examined to determine whether they have a specific type of adrenal tumor (pheochromocytoma). * Participants whose tumor does not secrete hormones will have a tumor biopsy to collect tissue for study. * Participants who have a large tumor or one that secretes hormones will have standard surgery to remove the tumor. Tissue will be collected for study. * Researchers will examine the collected tissue. They will try to determine whether the cells are cancerous or may become cancerous. * Participants will be asked to return to the National Institutes of Health Clinical Center every year for about 5 years. During these visits they will have imaging studies, lab tests, and a physical examination.
Primary Outcome
Feasibility of molecular testing in adrenal neoplasm fine needle aspiration (FNA) samples was determined by immunohistochemistry. Ribonucleic acid and deoxyribonucleic acid was extracted from fine needle aspiration and tumor tissue samples to differentiate between normal and abnormal tissue.
Interventions
- PROCEDURE Surgery
- PROCEDURE Tumor tissue biopsy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2011-05-04 |
| Est. Completion | 2018-01-12 |
Why NCT01348698 stopped before completion
NCT01348698 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 74 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which Surgery is the first listed.
NCT01348698 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01348698 about?
NCT01348698 is a clinical study titled "Evaluation of Molecular Markers in Adrenal Tumors". Background: \- Tumors of the adrenal gland are common. Most of them are not cancerous. However, there are no tests that can accurately tell which adrenal tumors are cancerous and which are not. The only way to tell is to remove the tumor with surgery and then examine it. Researchers have been using...
What is the current status of trial NCT01348698?
This trial is currently terminated. The enrollment target is 74 participants. The study started on 2011-05-04. Estimated completion is 2018-01-12.
What interventions are being tested in trial NCT01348698?
The interventions under investigation include: Surgery (PROCEDURE), Tumor tissue biopsy (PROCEDURE).
Who is sponsoring clinical trial NCT01348698?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03422731 · 74 participants · Early Phase 1
Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy
- NCT03804853 · 74 participants · NA
Rehabilitation Following Reverse Total Shoulder Arthroplasty
- NCT04065776 · 74 participants · NA
Evaluation of Hippocampal-Avoidance Using Proton Therapy in Low-Grade Glioma
- NCT04771156 · 74 participants · Phase 4
Ketorolac in Palatoplasty
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI